PD-1/PD-L1免疫抑制剂在宫颈癌中的最新研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i4.15525
Abstract
宫颈癌是严重危及女性健康的恶性肿瘤之一,其发病率呈上升状态,发病人群逐渐年轻化。当前,对于早期的宫颈癌的治疗方法主要为手术治疗,术后联合放疗和化疗。对于发现较晚的患者,主要为化学治疗联合免疫治疗/放射治疗及靶向治疗,该方法不良反应相对较大,对于发现较晚且转移的宫颈癌患者效果并不理想。因此,我们需要研究新的治疗方案,以此进一步提高宫颈癌患者的疗效,目前PD-1/PD-L1免疫抑制剂应用于宫颈癌的疗效初见佳绩,有望为未来攻克宫颈癌治疗提供巨大帮助。本文主要对PD-1/PD-L1免疫治疗当前在宫颈癌中的研究结果进行总结,以便为宫颈癌的免疫治疗提供相关思路。
Keywords
妇科肿瘤；宫颈癌；免疫治疗；PD-1 /PD-L1
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statist ics 2022:GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in 185 countries[J].CA:A Cancer Journal for Clinicians,2024,74(3):229-63.
[2] 任绮.白蛋白结合型紫杉醇对中晚期宫颈癌患者肿瘤负荷及疗效的影响 [J]. 基层医学论坛,2021,25(23):3312-3.
[3] N-R Datta,Stutz E, Liu M,et al.Concurrent chemoradiot herapy vs. radiotherapy alone in locally advanced cervix canc er:A systematic review and meta-analysis[J].Gynecol Oncol, 2017,145(2):374-385.
[4] W-J Koh, Abu-Rustum N-R,Bean S,et al.Cervical Cancer, Version 3.2019,NCCN Clinical Practice Guidelines in Oncology [J].J Natl Compr Canc Netw,2019,17(1):64-84.
[5] Youn, Jin Won.,Hur,Soo-Young., Woo, Jung Won.,Kim, Yong -Man.,Lim, Myong CheolPembrolizumab plus GX-188E therapeu tic DNA vaccine in patients with HPV-16-positive or HPV-18 -positive advanced cervical cancer: interim results of a single-arm,phase 2 trial. The Lancet.Oncology,2020,21(12).
[6] CHUA P T,LEE C L,HUANG K G.100% 5-Year Survival Rate in Laparoscopic Radical Hysterectomy for Early-Stage Cervic al Cancer is an Achievable Task[J].Gynecol Minim Invasive Ther,2020,9(2):53.
[7] 余一锋.奈达铂同期调强放疗治疗局部晚期鼻咽癌的临床研究[D].安徽医科大学,2015.
[8] 龙婷婷.奈达铂联合紫杉醇同步调强放疗治疗中晚期宫颈癌的疗效及不良反应的临床研究[D].安徽医科大学,2016.
[9] WRIGHT J D,MATSUO K,HUANG Y,et al.Prognostic Performa nce of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines[J].Obstetrics & Gynecology,2019,134(1):49-57.
[10] VORA C,GUPTA S.Targeted therapy in cervical cancer [J].ESMO Open, 2018, 3(Suppl 1):e000462.
[11] GENNIGENS C,JERUSALEM G,LAPAILLE L,et al.Recurrent or primary metastatic cervical cancer: current and future treatments[J].ESMO Open,2022,7(5).
[12] YANG W, SONG Y, LU Y L,et al.Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates wi th impaired cell‐mediated immunity in high-risk human papi llomavirus-related cervical intraepithelial neoplasia[J].Immu nology,2013,139(4):513-22.
[13] ABIKO K, MANDAI M, HAMANISHI J, et al. PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemi nation of Ovarian Cancer through CTL Dysfunction [J]. Clinical Cancer Research, 2013,19(6):1363-74.
[14] AKBARI O, STOCK P, SINGH A K, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airw ay hyperreactivity in opposing directions[J].Mucosal Immunol ogy,2010,3(1):81-91.
[15] Chung HC,Ros W,Delord JP,et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical canc er:results from the phase Ⅱ KEYNOTE-158 study[J].J Clin On col,2019,37(17):1470-1478.
[16] Chung H,Delord JP,Perets R,et al.Pembrolizumab treat ment of advanced cervical cancer:updated results from the phase Ⅱ KEYNOTE-158 study[J].Gynecol Oncol,2021,162(Supp l1):S27.
[17] Marabelle A,Fakih M,Lopez J,et al.Association of tum our mutational burden with outcomes in patients with advanc ed solid tumours treated with pembrolizumab：Prospective bio marker analysis of the multicohort,open-label,phase 2 KEYNO TE-158 study[J].Lancet Oncol,2020,21:1353-1365.
[18] PANG X,HUANG Z,ZHONG T,et al. Cadonilimab,a tetraval ent PD-1/CTLA-4 bispecific antibody with transbinding and enhanced target binding avidity[J]. MAbs,2023,15(1):2180794.
[19] Wu XH,Ji JF,Lou HM,et al. Efficacy and safety of cadoni limab,an anti-PD-1/CTLA4 bi-specific antibody,in previously treated recurrent or metastatic(R/M)cervical cancer:a multice nter,open-label,single-arm,phase Ⅱ trial(075)[J].Gynecol O ncol,2022,166(Suppl 1):S47-S48.
[20] Xia L,Wang J,Wang C,et al. Efficacy and safety of zimbe relimab(GLS-010)monotherapy in patients with recurrent or metastatic cervical cancer：a multicenter,single-arm,phaseⅡ study[J].Int J Gynecol Cancer,2023,33(12):1861-1868.
[21] LEE A,KEAM S J.Tislelizumab: First Approval[J].Drugs, 2020,80(6):617-24.
[22] ZHANG T, SONG X, XU L,et al.The binding of an antiPD-1 antibody to FcγRΙ has a profound impact on its biolog ical functions [J].Cancer immunology,immunotherapy:CII,2018, 67(7):1079-90.
[23] SHEN L, GUO J, ZHANG Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-co mparative, phase 1/2 study[J].Journal for immunotherapy of cancer,2020Jun;8(1):e000437.
[24] CHEN J, LI C, CAO Y,et al. Toripalimab combined with concurrent platinumbased Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial[J].BMC cancer,2022,22(1):793.
[25] J Zhu, et al.,J Clin Oncol 41,2023 ASCO (suppl 16;abstr 5531).
[26] 卓青婵.替雷利珠单抗治疗复发转移性宫颈癌的临床疗效与安全性分析:一项回顾性研究[D].广东医科大学,2023.
[27] Li J,Deng Y,Zhang W,et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors[J].J Hema tol Oncol,2021,14(1):95.
[28] Qin S,Li J,Zhong H,et al. Serplulimab,a novel anti-PD -1 antibody,in patients with microsatellite instability-high solid tu⁃mours：an open-label,single-arm,multicentre,phase Ⅱ trial[J].Br J Cancer,2022,127(12):2241-2248.
[29] Zhang B,Song Y,Luo S,et al. Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors：A multicenter phase 2 study[J]. Cell Rep Med,2023,4(12):101301.
[30] Lou H,Zhou Y,Li DP,et al. 251 Efficacy and safety of iparomlimab and tuvonralimab in previously treated patients with recurrent or metastatic cervical cancer：a multicenter, open-label,single-arm,phase 2 clinical trial(DUBHE-C-206)[J].Int J Gynecol Cancer,2024,34(Suppl1):A5.
[2] 任绮.白蛋白结合型紫杉醇对中晚期宫颈癌患者肿瘤负荷及疗效的影响 [J]. 基层医学论坛,2021,25(23):3312-3.
[3] N-R Datta,Stutz E, Liu M,et al.Concurrent chemoradiot herapy vs. radiotherapy alone in locally advanced cervix canc er:A systematic review and meta-analysis[J].Gynecol Oncol, 2017,145(2):374-385.
[4] W-J Koh, Abu-Rustum N-R,Bean S,et al.Cervical Cancer, Version 3.2019,NCCN Clinical Practice Guidelines in Oncology [J].J Natl Compr Canc Netw,2019,17(1):64-84.
[5] Youn, Jin Won.,Hur,Soo-Young., Woo, Jung Won.,Kim, Yong -Man.,Lim, Myong CheolPembrolizumab plus GX-188E therapeu tic DNA vaccine in patients with HPV-16-positive or HPV-18 -positive advanced cervical cancer: interim results of a single-arm,phase 2 trial. The Lancet.Oncology,2020,21(12).
[6] CHUA P T,LEE C L,HUANG K G.100% 5-Year Survival Rate in Laparoscopic Radical Hysterectomy for Early-Stage Cervic al Cancer is an Achievable Task[J].Gynecol Minim Invasive Ther,2020,9(2):53.
[7] 余一锋.奈达铂同期调强放疗治疗局部晚期鼻咽癌的临床研究[D].安徽医科大学,2015.
[8] 龙婷婷.奈达铂联合紫杉醇同步调强放疗治疗中晚期宫颈癌的疗效及不良反应的临床研究[D].安徽医科大学,2016.
[9] WRIGHT J D,MATSUO K,HUANG Y,et al.Prognostic Performa nce of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines[J].Obstetrics & Gynecology,2019,134(1):49-57.
[10] VORA C,GUPTA S.Targeted therapy in cervical cancer [J].ESMO Open, 2018, 3(Suppl 1):e000462.
[11] GENNIGENS C,JERUSALEM G,LAPAILLE L,et al.Recurrent or primary metastatic cervical cancer: current and future treatments[J].ESMO Open,2022,7(5).
[12] YANG W, SONG Y, LU Y L,et al.Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates wi th impaired cell‐mediated immunity in high-risk human papi llomavirus-related cervical intraepithelial neoplasia[J].Immu nology,2013,139(4):513-22.
[13] ABIKO K, MANDAI M, HAMANISHI J, et al. PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemi nation of Ovarian Cancer through CTL Dysfunction [J]. Clinical Cancer Research, 2013,19(6):1363-74.
[14] AKBARI O, STOCK P, SINGH A K, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airw ay hyperreactivity in opposing directions[J].Mucosal Immunol ogy,2010,3(1):81-91.
[15] Chung HC,Ros W,Delord JP,et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical canc er:results from the phase Ⅱ KEYNOTE-158 study[J].J Clin On col,2019,37(17):1470-1478.
[16] Chung H,Delord JP,Perets R,et al.Pembrolizumab treat ment of advanced cervical cancer:updated results from the phase Ⅱ KEYNOTE-158 study[J].Gynecol Oncol,2021,162(Supp l1):S27.
[17] Marabelle A,Fakih M,Lopez J,et al.Association of tum our mutational burden with outcomes in patients with advanc ed solid tumours treated with pembrolizumab：Prospective bio marker analysis of the multicohort,open-label,phase 2 KEYNO TE-158 study[J].Lancet Oncol,2020,21:1353-1365.
[18] PANG X,HUANG Z,ZHONG T,et al. Cadonilimab,a tetraval ent PD-1/CTLA-4 bispecific antibody with transbinding and enhanced target binding avidity[J]. MAbs,2023,15(1):2180794.
[19] Wu XH,Ji JF,Lou HM,et al. Efficacy and safety of cadoni limab,an anti-PD-1/CTLA4 bi-specific antibody,in previously treated recurrent or metastatic(R/M)cervical cancer:a multice nter,open-label,single-arm,phase Ⅱ trial(075)[J].Gynecol O ncol,2022,166(Suppl 1):S47-S48.
[20] Xia L,Wang J,Wang C,et al. Efficacy and safety of zimbe relimab(GLS-010)monotherapy in patients with recurrent or metastatic cervical cancer：a multicenter,single-arm,phaseⅡ study[J].Int J Gynecol Cancer,2023,33(12):1861-1868.
[21] LEE A,KEAM S J.Tislelizumab: First Approval[J].Drugs, 2020,80(6):617-24.
[22] ZHANG T, SONG X, XU L,et al.The binding of an antiPD-1 antibody to FcγRΙ has a profound impact on its biolog ical functions [J].Cancer immunology,immunotherapy:CII,2018, 67(7):1079-90.
[23] SHEN L, GUO J, ZHANG Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-co mparative, phase 1/2 study[J].Journal for immunotherapy of cancer,2020Jun;8(1):e000437.
[24] CHEN J, LI C, CAO Y,et al. Toripalimab combined with concurrent platinumbased Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial[J].BMC cancer,2022,22(1):793.
[25] J Zhu, et al.,J Clin Oncol 41,2023 ASCO (suppl 16;abstr 5531).
[26] 卓青婵.替雷利珠单抗治疗复发转移性宫颈癌的临床疗效与安全性分析:一项回顾性研究[D].广东医科大学,2023.
[27] Li J,Deng Y,Zhang W,et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors[J].J Hema tol Oncol,2021,14(1):95.
[28] Qin S,Li J,Zhong H,et al. Serplulimab,a novel anti-PD -1 antibody,in patients with microsatellite instability-high solid tu⁃mours：an open-label,single-arm,multicentre,phase Ⅱ trial[J].Br J Cancer,2022,127(12):2241-2248.
[29] Zhang B,Song Y,Luo S,et al. Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors：A multicenter phase 2 study[J]. Cell Rep Med,2023,4(12):101301.
[30] Lou H,Zhou Y,Li DP,et al. 251 Efficacy and safety of iparomlimab and tuvonralimab in previously treated patients with recurrent or metastatic cervical cancer：a multicenter, open-label,single-arm,phase 2 clinical trial(DUBHE-C-206)[J].Int J Gynecol Cancer,2024,34(Suppl1):A5.
Copyright © 2025 马生万, 金艳霞
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License